Canopy Growth (CGC) Q4 2025: $20M Cost Cuts Targeted as Medical Cannabis Outperforms Market
Canopy Growth’s decisive restructuring and a $20 million cost-cutting plan signal a shift toward disciplined execution and margin focus, even as operational complexity and U.S. exposure remain headwinds. Medical cannabis outperformance in Canada and a simplified portfolio are bright spots, but persistent international volatility and Canopy USA’s setbacks underscore the need for continued vigilance. Investors should watch for margin progress and execution on streamlined growth bets as fiscal 2026 unfolds.
Summary
- Canadian Medical Momentum: Medical cannabis business outperformed a declining market, gaining share and driving segment focus.
- Restructuring for Execution: Streamlined organization and $20 million in cost cuts aim to unlock margin and agility.
- U.S. Uncertainty Persists: Canopy USA’s underperformance and Acreage’s liquidity issues remain unresolved risks.
Performance Analysis
Canopy Growth’s Q4 results highlight the company’s ongoing transformation as leadership prioritizes margin expansion and operational focus after years of sprawling ambition. Net revenue in Canada rose 4% YoY, led by a 13% jump in medical cannabis sales, which notably outperformed a market estimated to have declined mid-single digits. This reflects a sharper focus on insurer-backed patients and a more tailored product assortment via the Spectrum online store, delivering clear market share gains.
Conversely, international cannabis sales fell 35% YoY (23% ex-U.S. CBD), pressured by regulatory shifts in Poland and increased competition in Australia. The Storz & Bickel vaporizer business, 23% of Q4 revenue, saw a 23% decline as device demand softened and promotional events underperformed. Adjusted gross margin in Canada dropped to 11% in Q4 due to new product launch costs and inventory write-downs, but full-year margin held at 25%. Management expects margin improvement as portfolio rationalization and automation drive efficiency.
- Canadian Medical Outperformance: Medical segment grew 13% YoY against a declining market, supporting leadership’s renewed focus.
- Portfolio Simplification: One-third of low-performing SKUs cut, shifting resources to high-velocity, higher-margin products.
- Cost Discipline: SG&A fell 28% YoY, and $20 million in annualized cost savings identified, with over half already executed.
Free cash flow improved on a full-year basis, but Q4 outflow increased due to higher CapEx and working capital. Balance sheet actions—including a $100 million U.S. term loan prepayment—reduced interest costs and extended debt maturity, supporting near-term liquidity.
Executive Commentary
"We're focusing our teams on the core category fundamentals, growing high quality cannabis efficiently, converting that cannabis into desirable products, and keeping these products in stock at the right price and with attractive margins... It's about simplification, synchronization, and executional excellence. That's the core of our plan going forward."
Luke Mongeau, Chief Executive Officer
"Q4 fiscal 25 fell short of our expectations, driven by lower revenue in stores and Bickel, Poland, and Australia medical businesses. These were partially offset by continued strength in our Canada and Germany medical and our continued cost discipline, which drove year-over-year improvement in adjusted EBITDA."
Judy Hong, Chief Financial Officer
Strategic Positioning
1. Canadian Medical Cannabis: Share Gains and Focus
Canopy’s Canadian medical business is now a central pillar, reporting directly to the CEO and benefiting from a unified global structure. The segment grew 13% in fiscal 2025, outpacing both the market and its largest competitor. This outperformance is attributed to insurer patient growth, a differentiated product mix, and a premium digital experience via Spectrum, online medical platform. Management’s strategy is to double down on high-value patients and leverage these operational learnings internationally.
2. Portfolio Rationalization and SKU Discipline
Leadership executed a major SKU rationalization, cutting one-third of low-performing products to focus on higher-velocity, higher-margin segments like high-potency flower, pre-rolls, and vapes. This sharper focus is already improving fill rates and enabling faster, more impactful innovation, such as the launch of advanced C-cell vapes and clayboard-infused pre-rolls under the Tweed and Seven Acres brands.
3. Centralized Operations for Margin and Agility
Operational restructuring now links supply chain and commercial teams under a global function, reporting directly to the CEO. The goal is to improve demand planning, product allocation, and execution across all markets. Early signs include fill rates rising from the mid-80s to mid-90s and automation upgrades in manufacturing to lower costs. A new stage-gate process for product launches aims to ensure margin accretion from day one.
4. U.S. Exposure and Canopy USA Challenges
Canopy USA, holding Jetty, Juana, and Acreage, remains a drag due to Acreage’s liquidity crisis and Ohio’s delayed adult-use rollout. Annualized revenue for Canopy USA is running at $210 million, far below the original $300 million target, with fair value of investments halved since June 2024. Management is monitoring the situation but remains bullish on long-term U.S. potential, especially if regulatory clarity improves.
5. Cost Structure and Financial Flexibility
The $20 million cost reduction program is being executed aggressively, with 80% of savings identified and over half already realized. These savings are designed to create “space in the P&L and balance sheet” for reinvestment, including targeted M&A. Early debt repayment and a new ATM program have improved liquidity and reduced annual interest expense by $13 million U.S.
Key Considerations
Canopy’s quarter marks a strategic inflection, with a clear pivot to disciplined execution and margin expansion after years of overextension. The company’s ability to sustain Canadian medical outperformance and deliver on cost reduction will be critical to restoring investor confidence and achieving positive adjusted EBITDA.
Key Considerations:
- Medical Cannabis as Core Engine: Outperformance and share gains in Canadian medical create a template for global expansion and margin stability.
- Execution Risk in International Markets: Regulatory shifts in Poland and competitive pressures in Australia highlight volatility and the need for nimble supply chain management.
- Margin Recovery Hinges on Cost Actions: Early automation and portfolio focus should support margin rebound, but execution must be sustained across all segments.
- U.S. Asset Volatility: Canopy USA’s performance is a material risk, with Acreage’s liquidity and Ohio’s slow rollout dragging on asset value and growth potential.
Risks
Regulatory uncertainty in key international markets, persistent competitive pressure, and execution risk around cost cuts and supply chain integration present ongoing challenges. Canopy USA’s underperformance and Acreage’s liquidity crisis could further impair asset value and strategic flexibility if not resolved. Margin recovery is not guaranteed, especially if Storz & Bickel’s demand softness persists or if new product launches fail to scale profitably.
Forward Outlook
For Q1 fiscal 2026, Canopy Growth expects:
- Continued strength in Canadian medical cannabis and incremental growth in Germany.
- Storz & Bickel sales to remain soft in H1, with improvement expected in H2 on new device launch.
For full-year 2026, management did not provide explicit revenue or EBITDA targets but reiterated priorities:
- Achieve positive adjusted EBITDA as soon as possible, driven by cost cuts and margin improvement.
- Annualized cost savings of at least $20 million to be realized over the next 12 to 18 months.
Management emphasized margin recovery in Canada, growth in global medical, and ongoing cost discipline as primary levers, but withheld specific timing for adjusted EBITDA inflection due to macro uncertainty and Storz & Bickel volatility.
- Watch for fill rate and margin improvement in Canada as leading indicators.
- Monitor U.S. regulatory developments and Acreage’s liquidity status for downside risk.
Takeaways
Canopy Growth’s renewed operational discipline and focus on profitable segments mark a substantive pivot, but execution risk remains high as the company navigates international volatility and U.S. asset drag.
- Medical Cannabis Drives Resilience: Outperformance in Canadian medical is a rare bright spot, supporting share gains and segment focus.
- Cost Reduction and Portfolio Focus Underpin Margin Story: Aggressive cost cuts and SKU rationalization are necessary but must translate into sustained gross margin recovery.
- U.S. and International Volatility Remain Watchpoints: Investors should scrutinize Canopy USA’s progress and regulatory shifts in key export markets as material drivers of future value.
Conclusion
Canopy Growth’s Q4 marks a clear pivot to disciplined execution, with medical cannabis outperformance and aggressive cost actions setting the stage for margin recovery. Sustained progress on these fronts, along with resolution of U.S. asset risks, will determine whether Canopy can translate its new structure into lasting shareholder value.
Industry Read-Through
Canopy’s strategic refocus and medical segment resilience signal that disciplined operators with strong insurer-backed patient bases can outperform even in declining markets. The company’s struggles with regulatory volatility in Poland and Australia, along with vaporizer demand softness, are cautionary signals for peers exposed to international medical and device markets. U.S. MSO (multi-state operator) volatility, as seen in Acreage’s struggles, highlights the ongoing risk for Canadian LPs betting on U.S. legalization or market expansion. Cost discipline and operational integration are likely to become industry-wide imperatives as capital markets remain tight and margin recovery becomes the primary lever for value creation.